A Phase 3 interventional study of Insulin degludec/liraglutide and Insulin degludec in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 37 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-19.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 — 4 open to participants now, 4 under way, 2 of them phase 3. insulin degludec · Diabetes Mellitus, Type 2.
Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, this one is the 25th largest by enrollment, is one of 5 that started in 2017, is one of 49 in phase 3, and was the 53rd registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →4 of the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:
Gan and Lee Pharmaceuticals, USA · Sites in Germany
Ages 18–70
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Sites in China
Ages 18–70
Yanbing Li
Ages 18–70
Tonghua Dongbao Pharmaceutical Co.,Ltd
Ages 18–75
By country, each count listing its studies:
insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 3 · Phase 3 50 · Phase 4 8
First in 2006; this study’s year is marked. 5 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 453 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 384 across the 70 interventional studies. Of the 64 that completed or were terminated, 51 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
59 of 70 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S: 25 open now, 29 under way, 11 of them phase 3. Of 603 finished, 174 (29%) have results posted.
Among the 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, this one is the 111th largest by enrollment of the 428 interventional ones that give a count, is one of 17 that started in 2017, is one of 187 in phase 3, and was the 438th registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
1 of the studies testing insulin degludec in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07173712Yanbing LiRegimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novo Nordisk A/S’s 643 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
This trial is conducted in Asia. The aim of this trial is to confirm the superiority of insulin degludec/liraglutide versus insulin degludec in controlling glycaemia in Chinese subjects with type 2 diabetes mellitus after 26 weeks of treatment
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
This study's enrollment of 453 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Inclusion Criteria: obtained before any trial-related activities. Trial-related activities are any procedures that are carried out as part of the trial, including procedures to determine suitability for the trial - Male or female, age at least 18 years at the time of signing inform consent - Type 2 diabetes mellitus (clinically diagnosed) - (glycosylated ) above or equal to 7.5% by central laboratory analysis, with the aim of a median of 8.5%. When approximately 50% of the randomised subjects have an HbA1c above 8.5%, the remaining subjects randomised must have an HbA1c below or equal to 8.5% or when approximately 50% of the subjects randomised have an HbA1c below or equal to 8.5%, the remaining subjects randomised must have an HbA1c above 8.5% - Current treatment for at least 90 calendar days prior to screening with basal insulin plus metformin plus/minus α-glucosidase inhibitors, sulphonylureas, glinides or thiazolidinediones. Subjects should be on a stable dose for at least 60 calendar days prior to screening of: Basal insulin 20-50 units (U)/day (both inclusive) ( Individual fluctuations of plus/minus 5U during the 60 day period prior to the day of screening are acceptable.) on the day of screening in combination with: - Metformin (above or equal to 1500 mg or max tolerated dose) or - Metformin (above or equal to 1500 mg or max tolerated dose) and sulphonylureas (above or equal to half of the max approved dose according to local label) or - Metformin (above or equal to 1500 mg or max tolerated dose) and glinide (at least half of the max approved dose according to local label) or - Metformin (above or equal to 1500 mg or max tolerated dose) and α-glucosidase inhibitors (AGI) (at least half of the max approved dose according to local label) or - Metformin (above or equal to 1500 mg or max tolerated dose) and thiazolidinediones (at least half of the max approved dose according to local label) - (BMI) above or equal to 24 kg/m\^2 Exclusion Criteria: Current use of any antidiabetic drug (except for basal insulin, metformin, α-glucosidase inhibitors, sulphonylureas, glinides or thiazolidinediones) or anticipated change in concomitant medication, that in the investigator´s opinion could interfere with glucose level (e.g. systemic ) - Treatment with glucagon like peptide -1 receptor agonists, or dipeptidyl-peptidase-4 inhibitors or insulin (except for basal insulin) within 90 days prior to Visit 1 - Impaired liver function defined as above or equal to 2.5 times upper normal range - Impaired renal function defined as serum-creatinine above or equal to 133 μmol/L for males and above or equal to 125 μmol/L for females, or as defined according to local for metformin Screening calcitonin above or equal to 50 ng/L - Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2) - Cardiac disorder defined as: congestive heart failure ( class III-IV), diagnosis of unstable angina pectoris, cerebral stroke and/or myocardial infarction within the last 12 months prior to screening and/or planned coronary, carotid or peripheral artery revascularisation procedures - Severe uncontrolled treated or untreated hypertension (systolic blood pressure above or equal to 180 mm Hg or diastolic blood pressure above or equal to 100 mm Hg) - Proliferative retinopathy or maculopathy (macular oedema) requiring acute treatment - History of pancreatitis (acute or chronic)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Insulin degludec/liraglutide
Drug: Insulin degludec
Drug pages: Insulin degludec · Liraglutide
Administered subcutaneously (s.c., under the skin) once daily in combination with metformin for the treatment duration of 26 weeks.
Administered subcutaneously (s.c., under the skin) once daily in combination with metformin for the treatment duration of 26 weeks.
Change in HbA1c
Change in glycosylated haemoglobin (HbA1c) from baseline (week 0) to week 26 is presented.
Time frame: Week 0, week 26
Change in Body Weight
Change in body weight from baseline (week 0) to week 26 is presented.
Time frame: Week 0, week 26
Number of Treatment-emergent Severe or Blood Glucose (BG) Confirmed Hypoglycaemic Episodes
Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the American Diabetes Association (ADA) classification (requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value \< 3.1 millimoles per liter (mmol/L) with or without symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Number of treatment-emergent severe or BG confirmed hypoglycaemic episodes during 26 weeks of treatment is presented.
Time frame: Up to 26 weeks
Change in Fasting Plasma Glucose (FPG)
Change in FPG from baseline (week 0) to week 26 is presented.
Time frame: Week 0, week 26
Change in Waist Circumference
Change in waist circumference from baseline (week 0) to week 26 is presented.
Time frame: Week 0, week 26
Change in Mean of the 9-point Self-measured Plasma Glucose (SMPG) Profile
Participants measured plasma glucose values using the blood glucose meter at 9 time points: before breakfast, 90 min after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 min after start of dinner, bedtime, at 4:00 am and before breakfast the following day. The mean of profile is defined as the area under the profile divided by measurement time and is calculated using the trapezoidal method. Change in mean of the 9-point SMPG profile from baseline (week 0) to week 26 is presented.
Time frame: Week 0, week 26
Change in SMPG-mean Post Prandial Increments
Participants measured plasma glucose values using the blood glucose meter at 9 time points: before breakfast, 90 min after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 min after start of dinner, bedtime, at 4:00 am and before breakfast the following day. Change in SMPG-mean postprandial increment over all meals from baseline (week 0) to week 26 is presented.
Time frame: Week 0, week 26
Insulin Dose
The mean of actual daily total insulin dose after 26 weeks of treatment is presented.
Time frame: Week 26
SMPG-9-point Profile (Individual Points in the Profile)
Participants measured plasma glucose values using the blood glucose meter at 9 time points: before breakfast, 90 min after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 min after start of dinner, bedtime, at 4:00 am and before breakfast the following day. SMPG-9-point profile (individual points in the profile) at week 26 is presented.
Time frame: Week 26
Change in Fasting High-density Lipoprotein (HDL) Cholesterol- Ratio to Baseline
Change in fasting HDL cholesterol (measured in mmol/L) from baseline (week 0) to week 26 is presented as ratio to baseline.
Time frame: Week 0, week 26
Change in Fasting Low-density Lipoprotein (LDL) Cholesterol- Ratio to Baseline
Change in fasting LDL cholesterol (measured in mmol/L) from baseline (week 0) to week 26 is presented as ratio to baseline.
Time frame: Week 0, week 26
Change in Fasting Very Low-density Lipoprotein (VLDL) Cholesterol- Ratio to Baseline
Change in fasting VLDL cholesterol (measured in mmol/L) from baseline (week 0) to week 26 is presented as ratio to baseline.
Time frame: Week 0, week 26
Change in Fasting Total Cholesterol- Ratio to Baseline
Change in fasting total cholesterol (measured in mmol/L) from baseline (week 0) to week 26 is presented as ratio to baseline.
Time frame: Week 0, week 26
Change in Fasting Triglycerides- Ratio to Baseline
Change in fasting triglycerides (measured in mmol/L) from baseline (week 0) to week 26 is presented as ratio to baseline.
Time frame: Week 0, week 26
Change in Fasting Free Fatty Acids- Ratio to Baseline
Change in fasting free fatty acids (measured in mmol/L) from baseline (week 0) to week 26 is presented as ratio to baseline.
Time frame: Week 0, week 26
Change in Fasting C-peptide- Ratio to Baseline
Change in fasting C-peptide (measured in nanomoles per liter (nmol/L)) from baseline (week 0) to week 26 is presented as ratio to baseline.
Time frame: Week 0, week 26
Change in Fasting Insulin- Ratio to Baseline
Change in fasting insulin (measured in picomoles per liter (pmol/L)) from baseline (week 0) to week 26 is presented as ratio to baseline.
Time frame: Week 0, week 26
Change in Fasting Glucagon- Ratio to Baseline
Change in fasting glucagon (measured in picograms per milliliter (pg/mL)) from baseline (week 0) to week 26 is presented as ratio to baseline.
Time frame: Week 0, week 26
Change in HOMA-B (Beta-cell Function)- Ratio to Baseline
Change in HOMA-B from baseline (week 0) to week 26 is presented as ratio to baseline.
Time frame: Week 0, week 26
Participants Who Achieved HbA1c < 7.0%, ADA Target (Yes/no)
Participants who achieved HbA1c \< 7.0%, ADA target (yes/no) is presented.
Time frame: Week 26
Participants Who Achieved HbA1c ≤ 6.5%, American Association of Clinical Endocrinologists (AACE) Target (Yes/no)
Participants who achieved HbA1c ≤ 6.5%, AACE target (yes/no) is presented.
Time frame: Week 26
Participants Who Achieved HbA1c < 7.0% and Change From Baseline in Body Weight Below or Equal to Zero
Participants who achieved HbA1c \< 7.0% and change from baseline in body weight below or equal to zero is presented.
Time frame: Week 26
Participants Who Achieved HbA1c ≤ 6.5% and Change From Baseline in Body Weight Below or Equal to Zero
Participants who achieved HbA1c ≤ 6.5% and change from baseline in body weight below or equal to zero is presented.
Time frame: Week 26
Participants Who Achieved HbA1c < 7.0% Without Treatment-emergent Severe or BG Confirmed Hypoglycaemic Episodes
Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value \< 3.1 mmol/L with or without symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Participants who achieved HbA1c \< 7.0% at week 26 without treatment-emergent severe or BG confirmed hypoglycaemic episodes during the last 12 weeks of treatment is presented.
Time frame: Week 26
Participants Who Achieved HbA1c ≤ 6.5% Without Treatment-emergent Severe or BG Confirmed Hypoglycaemic Episodes
Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value \< 3.1 mmol/L with or without symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Participants who achieved HbA1c ≤ 6.5% at week 26 without treatment-emergent severe or BG confirmed hypoglycaemic episodes during the last 12 weeks of treatment is presented.
Time frame: Week 26
Participants Who Achieved HbA1c < 7.0% and Change From Baseline in Body Weight Below or Equal to Zero and Without Treatment-emergent Severe or BG Confirmed Hypoglycaemic Episodes
Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value \< 3.1 mmol/L with or without symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Participants who achieved HbA1c \< 7.0% and change from baseline in body weight below or equal to zero and without treatment-emergent severe or BG confirmed hypoglycaemic episodes during the last 12 weeks of treatment is presented.
Time frame: Week 26
Participants Who Achieved HbA1c ≤ 6.5% and Change From Baseline in Body Weight Below or Equal to Zero and Without Treatment-emergent Severe or BG Confirmed Hypoglycaemic Episodes
Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value \< 3.1 mmol/L with or without symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Participants who achieved HbA1c ≤ 6.5% and change from baseline in body weight below or equal to zero and without treatment-emergent severe or BG confirmed hypoglycaemic episodes during the last 12 weeks of treatment is presented.
Time frame: Week 26
Number of Treatment-emergent Adverse Events (TEAEs)
A TEAE was defined as an adverse event with onset date on or after the first day of exposure to randomised treatment and no later than seven days after the last day of randomised treatment. If the event had onset date before the first day of exposure on randomised treatment and increased in severity during the treatment period and until 7 days after the last drug date, then this event was considered as a TEAE.
Time frame: Weeks 0-27
Number of Treatment-emergent Nocturnal Severe or BG Confirmed Hypoglycaemic Episodes
Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value \< 3.1 mmol/L with or without symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Nocturnal hypoglycaemic episodes were episodes occurring between 00:01 and 05.59 a.m. both inclusive. Number of treatment-emergent nocturnal severe or BG confirmed hypoglycaemic episodes is presented.
Time frame: Weeks 0-27
Number of Treatment-emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes
Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value \< 3.1 mmol/L with symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Number of treatment-emergent severe or BG confirmed symptomatic hypoglycaemic episodes is presented.
Time frame: Weeks 0-27
Number of Treatment-emergent Nocturnal Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes
Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value \< 3.1 mmol/L with symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Nocturnal hypoglycaemic episodes were episodes occurring between 00:01 and 05.59 a.m. both inclusive. Number of treatment-emergent nocturnal severe or BG confirmed symptomatic hypoglycaemic episodes is presented.
Time frame: Weeks 0-27
Number of Treatment-emergent Hypoglycaemic Episodes According to ADA Definition
Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Number of treatment-emergent hypoglycaemic episodes according to ADA definition is presented.
Time frame: Weeks 0-27
Change in Physical Examination
Physical examination parameters are categorised as cardiovascular system; central and peripheral nervous system; gastrointestinal system including mouth; general appearance; head, ears, eyes, nose, throat, neck; lymph node palpation; musculoskeletal system; respiratory system; skin and thyroid gland. The number of participants assessed as normal, abnormal not clinically significant (NCS) and abnormal clinically significant (CS) at week -2 and week 26 is presented.
Time frame: Week -2, week 26
Eye Examination
Dilated fundoscopy or fundus photography was performed by the investigator at week -2 and week 26. The results of the examination were interpreted for each eye (left/right) are categorised as normal, abnormal NCS or abnormal CS. Number of participants in each category at week -2 and week 26 were presented.
Time frame: Week -2, week 26
Change in Electrocardiogram (ECG)
The ECG was assessed by the investigator at baseline (week -2) and week 26 and categorised as normal, abnormal NCS or abnormal CS. Number of participants in each ECG category at baseline and week 26 were presented.
Time frame: Week -2, week 26
Change in Pulse
Change in pulse from baseline (week 0) to week 26 is presented.
Time frame: Week 0, week 26
Change in Blood Pressure (Systolic and Diastolic Blood Pressure)
Change in blood pressure (systolic and diastolic blood pressure) from baseline (week 0) to week 26 is presented.
Time frame: Week 0, week 26
Change in Biochemical Parameter- Amylase, Lipase, Creatinine Kinase, Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline Phosphatase (ALP)
Change in amylase, lipase, creatinine kinase, ALT, AST, ALP from baseline (week 0) to week 26 is presented.
Time frame: Week 0, week 26
Change in Biochemical Parameter-calcium (Total), Albumin Corrected Calcium, Potassium, Sodium, Urea
Change in calcium (total), albumin corrected calcium, potassium, sodium, urea from baseline (week 0) to week 26 is presented.
Time frame: Week 0, week 26
Change in Albumin
Change in albumin from baseline (week 0) to week 26 is presented.
Time frame: Week 0, week 26
Change in Total Bilirubin
Change in total bilirubin from baseline (week 0) to week 26 is presented.
Time frame: Week 0, week 26
Change in Creatinine
Change in creatinine from baseline (week 0) to week 26 is presented.
Time frame: Week 0, week 26
Change in Total Protein
Change in total protein from baseline (week 0) to week 26 is presented.
Time frame: Week 0, week 26
Change in Haematological Parameter- Haematocrit
Change in haematocrit from baseline (week 0) to week 26 is presented.
Time frame: Week 0, week 26
Change in Haematological Parameter- Haemoglobin
Change in haemoglobin from baseline (week 0) to week 26 is presented.
Time frame: Week 0, week 26
Change in Haematological Parameter- Leukocytes and Thrombocytes
Change in leukocytes and thrombocytes from baseline (week 0) to week 26 is presented.
Time frame: Week 0, week 26
Change in Haematological Parameter- Erythrocytes
Change in erythrocytes from baseline (week 0) to week 26 is presented.
Time frame: Week 0, week 26
Change in Haematological Parameter- Basophils
Change in basophils from baseline (week 0) to week 26 is presented.
Time frame: Week 0, week 26
Change in Haematological Parameter- Eosinophils
Change in eosinophils from baseline (week 0) to week 26 is presented.
Time frame: Week 0, week 26
Change in Haematological Parameter- Lymphocytes
Change in lymphocytes from baseline (week 0) to week 26 is presented.
Time frame: Week 0, week 26
Change in Haematological Parameter- Monocytes
Change in monocytes from baseline (week 0) to week 26 is presented.
Time frame: Week 0, week 26
Change in Haematological Parameter- Neutrophils
Change in neutrophils from baseline (week 0) to week 26 is presented.
Time frame: Week 0, week 26
Change in Calcitonin
Calcitonin levels were measured and were categorised as low, normal or high. Number of participants in each category at week 0 and week 26 were presented.
Time frame: Week 0, week 26
Urinalysis (Erythrocytes, Protein, Glucose and Ketones)
The urinalysis was the measurements of protein, glucose, erythrocytes and ketones at week 0 and week 26 and categorised as negative, trace, 1+, 2+ and 3+. Number of participants in each category at week 0 and week 26 are presented.
Time frame: Week 0, week 26
Anti-insulin Degludec Specific Antibodies
Serum samples were analysed for the presence of anti-insulin degludec specific antibodies. Results are presented as percentage of bound radioactivity-labelled insulin/total added radioactivity-labelled insulin (%B/T).
Time frame: Week 27
Antibodies Cross-reacting to Human Insulin
Serum samples were analysed for the presence of antibodies cross-reacting to human insulin. Results are presented as percentage of bound radioactivity-labelled insulin/total added radioactivity-labelled insulin (%B/T).
Time frame: Week 27
Total Insulin Antibodies
Serum samples were analysed for the presence of total insulin antibodies. Results are presented as percentage of bound radioactivity-labelled insulin/total added radioactivity-labelled insulin (%B/T).
Time frame: Week 27
Occurrence of Anti-liraglutide Antibodies (Yes/no)
This outcome measure is only applicable for the Insulin degludec/liraglutide treatment arm. Number of participants who measured with anti-liraglutide antibodies at week 27 are presented.
Time frame: Week 27
Occurrence of Anti-liraglutide Antibodies Cross Reacting Native Glucagon-like Peptide-1 (GLP-1)
This outcome measure is only applicable for the Insulin degludec/liraglutide treatment arm. Number of participants who measured with anti-liraglutide antibodies cross reacting native GLP-1 at week 27 are presented.
Time frame: Week 27
Occurrence of Neutralising Liraglutide Antibodies
This outcome measure is only applicable for the Insulin degludec/liraglutide treatment arm. Number of participants who measured with neutralising liraglutide antibodies at week 27 are presented.
Time frame: Week 27
Occurrence of Neutralising Liraglutide Antibodies Cross Reacting Native GLP-1
This outcome measure is only applicable for the Insulin degludec/liraglutide treatment arm. Number of participants who measured with neutralising liraglutide antibodies cross reacting native GLP-1 at week 27 are presented.
Time frame: Week 27
The trial was conducted at 40 sites in China.
| Milestone | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Started | 302 | 151 |
| Treated | 301 | 151 |
| Full analysis set (fas) | 302 | 151 |
| Safety analysis set (sas) | 301 | 151 |
| Completed | 290 | 139 |
| Not completed | 12 | 12 |
| Withdrew: Adverse event | 2 | 2 |
| Withdrew: Protocol violation | 5 | 2 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Withdrawal by subject | 2 | 5 |
| Withdrew: Other | 2 | 3 |
Change in glycosylated haemoglobin (HbA1c) from baseline (week 0) to week 26 is presented.
| Percentage point of HbA1c | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Change in HbA1c | -1.93 ± 1.14 | -1.06 ± 1.19 |
Change in body weight from baseline (week 0) to week 26 is presented.
| Kilogram (kg) | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Change in Body Weight | -0.7 ± 3.0 | 0.5 ± 2.7 |
Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the American Diabetes Association (ADA) classification (requiring assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value \< 3.1 millimoles per liter (mmol/L) with or without symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Number of treatment-emergent severe or BG confirmed hypoglycaemic episodes during 26 weeks of treatment is presented.
| Episodes | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Number of Treatment-emergent Severe or Blood Glucose (BG) Confirmed Hypoglycaemic Episodes | 38 | 36 |
Change in FPG from baseline (week 0) to week 26 is presented.
| mmol/L | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Change in Fasting Plasma Glucose (FPG) | -3.57 ± 3.00 | -2.82 ± 3.15 |
Change in waist circumference from baseline (week 0) to week 26 is presented.
| Centimeter (cm) | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Change in Waist Circumference | -0.4 ± 4.3 | 0.7 ± 3.3 |
Participants measured plasma glucose values using the blood glucose meter at 9 time points: before breakfast, 90 min after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 min after start of dinner, bedtime, at 4:00 am and before breakfast the following day. The mean of profile is defined as the area under the profile divided by measurement time and is calculated using the trapezoidal method. Change in mean of the 9-point SMPG profile from baseline (week 0) to week 26 is presented.
| mmol/L | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Change in Mean of the 9-point Self-measured Plasma Glucose (SMPG) Profile | -3.35 ± 2.63 | -2.31 ± 2.61 |
Participants measured plasma glucose values using the blood glucose meter at 9 time points: before breakfast, 90 min after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 min after start of dinner, bedtime, at 4:00 am and before breakfast the following day. Change in SMPG-mean postprandial increment over all meals from baseline (week 0) to week 26 is presented.
| mmol/L | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Change in SMPG-mean Post Prandial Increments | 0.08 ± 2.19 | 0.28 ± 2.71 |
The mean of actual daily total insulin dose after 26 weeks of treatment is presented.
| Units of insulin (U) | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Insulin Dose | 34.6 ± 11.1 | 37.9 ± 10.8 |
Participants measured plasma glucose values using the blood glucose meter at 9 time points: before breakfast, 90 min after start of breakfast, before lunch, 90 minutes after start of lunch, before dinner, 90 min after start of dinner, bedtime, at 4:00 am and before breakfast the following day. SMPG-9-point profile (individual points in the profile) at week 26 is presented.
| mmol/L | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Before breakfast | 5.48 ± 1.06 | 5.88 ± 1.30 |
| 90 minutes after start of breakfast | 9.51 ± 2.66 | 10.50 ± 2.45 |
| Before lunch | 6.93 ± 2.10 | 8.17 ± 3.19 |
| 90 minutes after start of lunch | 9.68 ± 2.52 | 11.21 ± 2.93 |
| Before main evening meal | 7.24 ± 2.16 | 7.87 ± 2.65 |
| 90 minutes after main evening meal | 9.87 ± 2.53 | 10.86 ± 2.46 |
| At bedtime | 8.57 ± 2.52 | 9.52 ± 2.61 |
| At 4:00 a.m. | 5.97 ± 1.49 | 6.61 ± 1.99 |
| Before breakfast the following day | 5.48 ± 1.14 | 5.83 ± 1.52 |
Change in fasting HDL cholesterol (measured in mmol/L) from baseline (week 0) to week 26 is presented as ratio to baseline.
| Ratio of HDL cholesterol | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Change in Fasting High-density Lipoprotein (HDL) Cholesterol- Ratio to Baseline | 1.00 ± 17.5 | 1.03 ± 15.9 |
Change in fasting LDL cholesterol (measured in mmol/L) from baseline (week 0) to week 26 is presented as ratio to baseline.
| Ratio of LDL cholesterol | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Change in Fasting Low-density Lipoprotein (LDL) Cholesterol- Ratio to Baseline | 0.89 ± 32.5 | 0.95 ± 37.7 |
Change in fasting VLDL cholesterol (measured in mmol/L) from baseline (week 0) to week 26 is presented as ratio to baseline.
| Ratio of VLDL cholesterol | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Change in Fasting Very Low-density Lipoprotein (VLDL) Cholesterol- Ratio to Baseline | 0.92 ± 55.2 | 0.93 ± 49.1 |
Change in fasting total cholesterol (measured in mmol/L) from baseline (week 0) to week 26 is presented as ratio to baseline.
| Ratio of total cholesterol | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Change in Fasting Total Cholesterol- Ratio to Baseline | 0.92 ± 19.1 | 0.97 ± 20.0 |
Change in fasting triglycerides (measured in mmol/L) from baseline (week 0) to week 26 is presented as ratio to baseline.
| Ratio of triglycerides | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Change in Fasting Triglycerides- Ratio to Baseline | 0.91 ± 63.7 | 0.92 ± 55.8 |
Change in fasting free fatty acids (measured in mmol/L) from baseline (week 0) to week 26 is presented as ratio to baseline.
| Ratio of free fatty acids | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Change in Fasting Free Fatty Acids- Ratio to Baseline | 0.65 ± 76.4 | 0.64 ± 61.9 |
Change in fasting C-peptide (measured in nanomoles per liter (nmol/L)) from baseline (week 0) to week 26 is presented as ratio to baseline.
| Ratio of C-peptide | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Change in Fasting C-peptide- Ratio to Baseline | 0.64 ± 71.2 | 0.52 ± 71.8 |
Change in fasting insulin (measured in picomoles per liter (pmol/L)) from baseline (week 0) to week 26 is presented as ratio to baseline.
| Ratio of insulin | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Change in Fasting Insulin- Ratio to Baseline | 0.63 ± 118.3 | 0.50 ± 106.4 |
Change in fasting glucagon (measured in picograms per milliliter (pg/mL)) from baseline (week 0) to week 26 is presented as ratio to baseline.
| Ratio of glucagon | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Change in Fasting Glucagon- Ratio to Baseline | 1.01 ± 95.8 | 1.09 ± 81.7 |
Change in HOMA-B from baseline (week 0) to week 26 is presented as ratio to baseline.
| Ratio of beta-cell function | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Change in HOMA-B (Beta-cell Function)- Ratio to Baseline | 1.47 ± 115.0 | 0.99 ± 113.4 |
Participants who achieved HbA1c \< 7.0%, ADA target (yes/no) is presented.
| Participants | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Yes | 151 | 23 |
| No | 138 | 115 |
Participants who achieved HbA1c ≤ 6.5%, AACE target (yes/no) is presented.
| Participants | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Yes | 96 | 10 |
| No | 193 | 128 |
Participants who achieved HbA1c \< 7.0% and change from baseline in body weight below or equal to zero is presented.
| Participants | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Yes | 98 | 7 |
| No | 204 | 144 |
Participants who achieved HbA1c ≤ 6.5% and change from baseline in body weight below or equal to zero is presented.
| Participants | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Yes | 59 | 3 |
| No | 243 | 148 |
Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value \< 3.1 mmol/L with or without symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Participants who achieved HbA1c \< 7.0% at week 26 without treatment-emergent severe or BG confirmed hypoglycaemic episodes during the last 12 weeks of treatment is presented.
| Participants | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Yes | 148 | 22 |
| No | 154 | 129 |
Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value \< 3.1 mmol/L with or without symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Participants who achieved HbA1c ≤ 6.5% at week 26 without treatment-emergent severe or BG confirmed hypoglycaemic episodes during the last 12 weeks of treatment is presented.
| Participants | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Yes | 93 | 9 |
| No | 209 | 142 |
Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value \< 3.1 mmol/L with or without symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Participants who achieved HbA1c \< 7.0% and change from baseline in body weight below or equal to zero and without treatment-emergent severe or BG confirmed hypoglycaemic episodes during the last 12 weeks of treatment is presented.
| Participants | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Yes | 94 | 7 |
| No | 208 | 144 |
Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value \< 3.1 mmol/L with or without symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Participants who achieved HbA1c ≤ 6.5% and change from baseline in body weight below or equal to zero and without treatment-emergent severe or BG confirmed hypoglycaemic episodes during the last 12 weeks of treatment is presented.
| Participants | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Yes | 58 | 3 |
| No | 244 | 148 |
A TEAE was defined as an adverse event with onset date on or after the first day of exposure to randomised treatment and no later than seven days after the last day of randomised treatment. If the event had onset date before the first day of exposure on randomised treatment and increased in severity during the treatment period and until 7 days after the last drug date, then this event was considered as a TEAE.
| Adverse events | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Number of Treatment-emergent Adverse Events (TEAEs) | 641 | 230 |
Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value \< 3.1 mmol/L with or without symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Nocturnal hypoglycaemic episodes were episodes occurring between 00:01 and 05.59 a.m. both inclusive. Number of treatment-emergent nocturnal severe or BG confirmed hypoglycaemic episodes is presented.
| Episodes | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Number of Treatment-emergent Nocturnal Severe or BG Confirmed Hypoglycaemic Episodes | 9 | 8 |
Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value \< 3.1 mmol/L with symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Number of treatment-emergent severe or BG confirmed symptomatic hypoglycaemic episodes is presented.
| Episodes | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Number of Treatment-emergent Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes | 23 | 21 |
Severe or BG confirmed hypoglycaemic episodes were defined as episodes that were severe according to the ADA classification (required assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions) or BG confirmed by a plasma glucose value \< 3.1 mmol/L with symptoms consistent with hypoglycaemia. Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Nocturnal hypoglycaemic episodes were episodes occurring between 00:01 and 05.59 a.m. both inclusive. Number of treatment-emergent nocturnal severe or BG confirmed symptomatic hypoglycaemic episodes is presented.
| Episodes | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Number of Treatment-emergent Nocturnal Severe or BG Confirmed Symptomatic Hypoglycaemic Episodes | 7 | 7 |
Hypoglycaemic episodes were defined as treatment-emergent if the onset of the episode occurred on or after the first day of trial product administration, and no later than 7 calendar days after the last day on trial product. Number of treatment-emergent hypoglycaemic episodes according to ADA definition is presented.
| Episodes | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Number of Treatment-emergent Hypoglycaemic Episodes According to ADA Definition | 1099 | 680 |
Physical examination parameters are categorised as cardiovascular system; central and peripheral nervous system; gastrointestinal system including mouth; general appearance; head, ears, eyes, nose, throat, neck; lymph node palpation; musculoskeletal system; respiratory system; skin and thyroid gland. The number of participants assessed as normal, abnormal not clinically significant (NCS) and abnormal clinically significant (CS) at week -2 and week 26 is presented.
| Participants | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Week-2: Cardiovascular system — Normal | 299 | 149 |
| Week-2: Cardiovascular system — Abnormal NCS | 1 | 0 |
| Week-2: Cardiovascular system — Abnormal CS | 1 | 2 |
| Week 26: Cardiovascular system — Normal | 286 | 137 |
| Week 26: Cardiovascular system — Abnormal NCS | 1 | 0 |
| Week 26: Cardiovascular system — Abnormal CS | 1 | 2 |
| Week-2: Central and peripheral nervous system — Normal | 299 | 150 |
| Week-2: Central and peripheral nervous system — Abnormal NCS | 2 | 0 |
| Week-2: Central and peripheral nervous system — Abnormal CS | 0 | 1 |
| Week 26: Central and peripheral nervous system — Normal | 287 | 139 |
| Week 26: Central and peripheral nervous system — Abnormal NCS | 1 | 0 |
| Week 26: Central and peripheral nervous system — Abnormal CS | 0 | 0 |
| Week -2: Gastrointestinal system — Normal | 299 | 150 |
| Week -2: Gastrointestinal system — Abnormal NCS | 2 | 1 |
| Week -2: Gastrointestinal system — Abnormal CS | 0 | 0 |
| Week 26: Gastrointestinal system — Normal | 285 | 139 |
| Week 26: Gastrointestinal system — Abnormal NCS | 2 | 0 |
| Week 26: Gastrointestinal system — Abnormal CS | 1 | 0 |
| Week -2: General appearance — Normal | 283 | 141 |
| Week -2: General appearance — Abnormal NCS | 11 | 2 |
| Week -2: General appearance — Abnormal CS | 7 | 8 |
| Week 26: General appearance — Normal | 273 | 130 |
| Week 26: General appearance — Abnormal NCS | 9 | 2 |
| Week 26: General appearance — Abnormal CS | 6 | 7 |
| Week -2: Head, eyes, ENTand Neck — Normal | 295 | 147 |
| Week -2: Head, eyes, ENTand Neck — Abnormal NCS | 2 | 2 |
| Week -2: Head, eyes, ENTand Neck — Abnormal CS | 4 | 2 |
| Week 26: Head, eyes, ENTand Neck — Normal | 283 | 137 |
| Week 26: Head, eyes, ENTand Neck — Abnormal NCS | 2 | 1 |
| Week 26: Head, eyes, ENTand Neck — Abnormal CS | 3 | 1 |
| Week -2: Lymph node palpation — Normal | 301 | 151 |
| Week -2: Lymph node palpation — Abnormal NCS | 0 | 0 |
| Week -2: Lymph node palpation — Abnormal CS | 0 | 0 |
| Week 26: Lymph node palpation — Normal | 288 | 139 |
| Week 26: Lymph node palpation — Abnormal NCS | 0 | 0 |
| Week 26: Lymph node palpation — Abnormal CS | 0 | 0 |
| Week -2: Musculoskeletal system — Normal | 296 | 145 |
| Week -2: Musculoskeletal system — Abnormal NCS | 2 | 3 |
| Week -2: Musculoskeletal system — Abnormal CS | 3 | 3 |
| Week 26: Musculoskeletal system — Normal | 280 | 137 |
| Week 26: Musculoskeletal system — Abnormal NCS | 3 | 1 |
| Week 26: Musculoskeletal system — Abnormal CS | 5 | 1 |
| Week -2: Respiratory system — Normal | 301 | 151 |
| Week -2: Respiratory system — Abnormal NCS | 0 | 0 |
| Week -2: Respiratory system — Abnormal CS | 0 | 0 |
| Week 26: Respiratory system — Normal | 288 | 139 |
| Week 26: Respiratory system — Abnormal NCS | 0 | 0 |
| Week 26: Respiratory system — Abnormal CS | 0 | 0 |
| Week -2: Skin — Normal | 270 | 132 |
| Week -2: Skin — Abnormal NCS | 22 | 13 |
| Week -2: Skin — Abnormal CS | 9 | 6 |
| Week 26: Skin — Normal | 259 | 126 |
| Week 26: Skin — Abnormal NCS | 22 | 9 |
| Week 26: Skin — Abnormal CS | 7 | 4 |
| Week -2: Thyroid gland — Normal | 295 | 147 |
| Week -2: Thyroid gland — Abnormal NCS | 4 | 2 |
| Week -2: Thyroid gland — Abnormal CS | 2 | 2 |
| Week 26: Thyroid gland — Normal | 284 | 134 |
| Week 26: Thyroid gland — Abnormal NCS | 3 | 3 |
| Week 26: Thyroid gland — Abnormal CS | 1 | 2 |
Dilated fundoscopy or fundus photography was performed by the investigator at week -2 and week 26. The results of the examination were interpreted for each eye (left/right) are categorised as normal, abnormal NCS or abnormal CS. Number of participants in each category at week -2 and week 26 were presented.
| Participants | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Week -2: Left eye — Normal | 167 | 87 |
| Week -2: Left eye — Abnormal NCS | 34 | 15 |
| Week -2: Left eye — Abnormal CS | 100 | 49 |
| Week 26: Left eye — Normal | 147 | 80 |
| Week 26: Left eye — Abnormal NCS | 35 | 14 |
| Week 26: Left eye — Abnormal CS | 105 | 45 |
| Week -2: Right eye — Normal | 162 | 85 |
| Week -2: Right eye — Abnormal NCS | 41 | 18 |
| Week -2: Right eye — Abnormal CS | 98 | 47 |
| Week 26: Right eye — Normal | 139 | 84 |
| Week 26: Right eye — Abnormal NCS | 37 | 12 |
| Week 26: Right eye — Abnormal CS | 111 | 42 |
The ECG was assessed by the investigator at baseline (week -2) and week 26 and categorised as normal, abnormal NCS or abnormal CS. Number of participants in each ECG category at baseline and week 26 were presented.
| Participants | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Week -2 — Normal | 175 | 90 |
| Week -2 — Abnormal NCS | 76 | 41 |
| Week -2 — Abnormal CS | 50 | 20 |
| Week 26 — Normal | 175 | 91 |
| Week 26 — Abnormal NCS | 73 | 32 |
| Week 26 — Abnormal CS | 39 | 16 |
Change in pulse from baseline (week 0) to week 26 is presented.
| Beats per minute (beats/min) | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Change in Pulse | 5.7 ± 9.6 | 1.3 ± 8.7 |
Change in blood pressure (systolic and diastolic blood pressure) from baseline (week 0) to week 26 is presented.
| Millimeters of mercury (mmHg) | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Systolic blood pressure | -3.5 ± 13.6 | -0.5 ± 12.5 |
| Diastolic blood pressure | 0.1 ± 7.8 | -0.4 ± 8.1 |
Change in amylase, lipase, creatinine kinase, ALT, AST, ALP from baseline (week 0) to week 26 is presented.
| Units per liter (U/L) | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Amylase | 10.45 ± 23.14 | 2.69 ± 11.72 |
| Lipase | 16.97 ± 35.24 | -0.35 ± 13.81 |
| Creatinine kinase | 3.32 ± 65.17 | 6.99 ± 84.31 |
| ALT | -3.02 ± 12.03 | -4.06 ± 11.97 |
| AST | -1.42 ± 7.46 | -2.06 ± 7.92 |
| ALP | -1.62 ± 13.30 | -1.70 ± 11.39 |
Change in calcium (total), albumin corrected calcium, potassium, sodium, urea from baseline (week 0) to week 26 is presented.
| mmol/L | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Calcium (total) | 0.01 ± 0.10 | -0.01 ± 0.09 |
| Albumin corrected calcium | -0.00 ± 0.08 | -0.01 ± 0.08 |
| Potassium | -0.03 ± 0.34 | -0.11 ± 0.35 |
| Sodium | 1.03 ± 2.47 | 1.40 ± 2.43 |
| Urea | -0.09 ± 1.32 | 0.17 ± 1.29 |
Change in albumin from baseline (week 0) to week 26 is presented.
| Grams per deciliter (g/dL) | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Change in Albumin | 0.05 ± 0.29 | 0.02 ± 0.25 |
Change in total bilirubin from baseline (week 0) to week 26 is presented.
| Micromoles per liter (umol/L) | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Change in Total Bilirubin | -0.30 ± 3.89 | -0.54 ± 3.66 |
Change in creatinine from baseline (week 0) to week 26 is presented.
| umol/L | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Change in Creatinine | 0.44 ± 7.93 | -0.32 ± 7.52 |
Change in total protein from baseline (week 0) to week 26 is presented.
| g/dL | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Change in Total Protein | 0.08 ± 0.41 | 0.03 ± 0.39 |
Change in haematocrit from baseline (week 0) to week 26 is presented.
| Percentage of red blood cells | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Change in Haematological Parameter- Haematocrit | -0.07 ± 2.56 | -0.12 ± 2.14 |
Change in haemoglobin from baseline (week 0) to week 26 is presented.
| mmol/L | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Change in Haematological Parameter- Haemoglobin | -0.08 ± 0.52 | -0.09 ± 0.41 |
Change in leukocytes and thrombocytes from baseline (week 0) to week 26 is presented.
| 10^9 cells per liter (10^9/L) | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Leukocytes | 0.32 ± 1.39 | 0.31 ± 1.18 |
| Thrombocytes | 14.13 ± 34.34 | 12.19 ± 34.01 |
Change in erythrocytes from baseline (week 0) to week 26 is presented.
| 10^12 cells per liter (10^12/L) | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Change in Haematological Parameter- Erythrocytes | -0.06 ± 0.26 | -0.05 ± 0.24 |
Change in basophils from baseline (week 0) to week 26 is presented.
| Percentage of basophils | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Change in Haematological Parameter- Basophils | 0.00 ± 0.34 | 0.01 ± 0.27 |
Change in eosinophils from baseline (week 0) to week 26 is presented.
| Percentage of eosinophils | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Change in Haematological Parameter- Eosinophils | -0.15 ± 1.84 | -0.25 ± 1.72 |
Change in lymphocytes from baseline (week 0) to week 26 is presented.
| Percentage of lymphocytes | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Change in Haematological Parameter- Lymphocytes | -1.00 ± 6.95 | -0.82 ± 6.41 |
Change in monocytes from baseline (week 0) to week 26 is presented.
| Percentage of monocytes | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Change in Haematological Parameter- Monocytes | -0.19 ± 2.02 | -0.06 ± 2.19 |
Change in neutrophils from baseline (week 0) to week 26 is presented.
| Percentage of neutrophils | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Change in Haematological Parameter- Neutrophils | 1.34 ± 7.85 | 0.99 ± 7.41 |
Calcitonin levels were measured and were categorised as low, normal or high. Number of participants in each category at week 0 and week 26 were presented.
| Participants | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Week 0 — Low | 0 | 0 |
| Week 0 — Normal | 293 | 149 |
| Week 0 — High | 8 | 2 |
| Week 26 — Low | 0 | 0 |
| Week 26 — Normal | 279 | 136 |
| Week 26 — High | 10 | 3 |
The urinalysis was the measurements of protein, glucose, erythrocytes and ketones at week 0 and week 26 and categorised as negative, trace, 1+, 2+ and 3+. Number of participants in each category at week 0 and week 26 are presented.
| Participants | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Week 0: Erythrocytes — Negative | 258 | 121 |
| Week 0: Erythrocytes — Trace | 33 | 22 |
| Week 0: Erythrocytes — 1+ | 3 | 4 |
| Week 0: Erythrocytes — 2+ | 2 | 3 |
| Week 0: Erythrocytes — 3+ | 4 | 1 |
| Week 26: Erythrocytes — Negative | 255 | 120 |
| Week 26: Erythrocytes — Trace | 22 | 11 |
| Week 26: Erythrocytes — 1+ | 6 | 1 |
| Week 26: Erythrocytes — 2+ | 2 | 4 |
| Week 26: Erythrocytes — 3+ | 2 | 3 |
| Week 0: Glucose — Negative | 171 | 92 |
| Week 0: Glucose — Trace | 33 | 13 |
| Week 0: Glucose — 1+ | 30 | 17 |
| Week 0: Glucose — 2+ | 25 | 13 |
| Week 0: Glucose — 3+ | 41 | 16 |
| Week 26: Glucose — Negative | 256 | 110 |
| Week 26: Glucose — Trace | 14 | 16 |
| Week 26: Glucose — 1+ | 10 | 9 |
| Week 26: Glucose — 2+ | 4 | 2 |
| Week 26: Glucose — 3+ | 3 | 2 |
| Week 0: Ketones — Negative | 274 | 137 |
| Week 0: Ketones — Trace | 21 | 10 |
| Week 0: Ketones — 1+ | 5 | 4 |
| Week 0: Ketones — 2+ | 0 | 0 |
| Week 0: Ketones — 3+ | 0 | 0 |
| Week 26: Ketones — Negative | 272 | 132 |
| Week 26: Ketones — Trace | 14 | 7 |
| Week 26: Ketones — 1+ | 1 | 0 |
| Week 26: Ketones — 2+ | 0 | 0 |
| Week 26: Ketones — 3+ | 0 | 0 |
| Week 0: Protein — Negative | 172 | 89 |
| Week 0: Protein — Trace | 72 | 32 |
| Week 0: Protein — 1+ | 36 | 18 |
| Week 0: Protein — 2+ | 16 | 10 |
| Week 0: Protein — 3+ | 4 | 2 |
| Week 26: Protein — Negative | 198 | 89 |
| Week 26: Protein — Trace | 47 | 22 |
| Week 26: Protein — 1+ | 29 | 18 |
| Week 26: Protein — 2+ | 11 | 9 |
| Week 26: Protein — 3+ | 2 | 1 |
Serum samples were analysed for the presence of anti-insulin degludec specific antibodies. Results are presented as percentage of bound radioactivity-labelled insulin/total added radioactivity-labelled insulin (%B/T).
| %B/T | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Anti-insulin Degludec Specific Antibodies | 0.25 ± 1.25 | 0.13 ± 0.57 |
Serum samples were analysed for the presence of antibodies cross-reacting to human insulin. Results are presented as percentage of bound radioactivity-labelled insulin/total added radioactivity-labelled insulin (%B/T).
| %B/T | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Antibodies Cross-reacting to Human Insulin | 9.07 ± 16.61 | 8.64 ± 16.84 |
Serum samples were analysed for the presence of total insulin antibodies. Results are presented as percentage of bound radioactivity-labelled insulin/total added radioactivity-labelled insulin (%B/T).
| %B/T | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Total Insulin Antibodies | 9.31 ± 17.33 | 8.77 ± 17.19 |
This outcome measure is only applicable for the Insulin degludec/liraglutide treatment arm. Number of participants who measured with anti-liraglutide antibodies at week 27 are presented.
| Participants | Insulin Degludec/Liraglutide |
|---|---|
| Yes | 24 |
| No | 264 |
This outcome measure is only applicable for the Insulin degludec/liraglutide treatment arm. Number of participants who measured with anti-liraglutide antibodies cross reacting native GLP-1 at week 27 are presented.
| Participants | Insulin Degludec/Liraglutide |
|---|---|
| Yes | 6 |
This outcome measure is only applicable for the Insulin degludec/liraglutide treatment arm. Number of participants who measured with neutralising liraglutide antibodies at week 27 are presented.
| Participants | Insulin Degludec/Liraglutide |
|---|---|
| Yes | 0 |
This outcome measure is only applicable for the Insulin degludec/liraglutide treatment arm. Number of participants who measured with neutralising liraglutide antibodies cross reacting native GLP-1 at week 27 are presented.
| Participants | Insulin Degludec/Liraglutide |
|---|---|
| Yes | 0 |
Collected over Weeks 0-30. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Insulin Degludec/Liraglutide | 0/301 (0%) | 13/301 (4.3%) | 113/301 (37.5%) |
| Insulin Degludec | 0/151 (0%) | 7/151 (4.6%) | 43/151 (28.5%) |
| Event | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Coronary artery diseaseCardiac disorders | 0/301 | 2/151 |
| Angina unstableCardiac disorders | 1/301 | 1/151 |
| Cerebral infarctionNervous system disorders | 0/301 | 1/151 |
| Coronary artery stenosisCardiac disorders | 0/301 | 1/151 |
| EpiglottitisInfections and infestations | 0/301 | 1/151 |
| Femur fractureInjury, poisoning and procedural complications | 0/301 | 1/151 |
| CataractEye disorders | 1/301 | 0/151 |
| ConstipationGastrointestinal disorders | 1/301 | 0/151 |
| DiarrhoeaGastrointestinal disorders | 1/301 | 0/151 |
| Fibroadenoma of breastNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/301 | 0/151 |
| Event | Insulin Degludec/Liraglutide | Insulin Degludec |
|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 38/301 | 27/151 |
| Lipase increasedInvestigations | 36/301 | 3/151 |
| Diabetic retinopathyEye disorders | 35/301 | 11/151 |
| DiarrhoeaGastrointestinal disorders | 22/301 | 2/151 |
| Decreased appetiteMetabolism and nutrition disorders | 21/301 | 3/151 |
Full analysis set (FAS) included all randomised participants.
| Age, Continuous(Years) | Insulin Degludec/Liraglutide | Insulin Degludec | Total |
|---|---|---|---|
| Mean | 54.5 ± 9.8 | 55.3 ± 10.0 | 54.7 ± 9.9 |
| Sex: Female, Male(Participants) | Insulin Degludec/Liraglutide | Insulin Degludec | Total |
|---|---|---|---|
| Female | 119 | 60 | 179 |
| Male | 183 | 91 | 274 |
| Ethnicity (NIH/OMB)(Participants) | Insulin Degludec/Liraglutide | Insulin Degludec | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 302 | 151 | 453 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Insulin Degludec/Liraglutide | Insulin Degludec | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 302 | 151 | 453 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Glycosylated haemoglobin (HbA1c)(Percentage of HbA1c) | Insulin Degludec/Liraglutide | Insulin Degludec | Total |
|---|---|---|---|
| Mean | 8.93 ± 1.20 | 8.96 ± 1.17 | 8.94 ± 1.19 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes
Ran from May 2017 to primary completion in Mar 2019, 21 months.
Results were first posted in Mar 2020, 1 year after primary completion.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 21 months is above that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Insulin degludec · Liraglutide